New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
11:34 EDTEARSAuris Medical opens for trade at $6.00, IPO priced at $6.00
News For EARS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 14, 2015
05:34 EDTEARSAuris Medical achieves 50% enrollment in TACTT3 clinical trial
Auris Medical announced that it has enrolled the first 150 patients with post-acute tinnitus in Stratum B of the company's ongoing TACTT3 clinical trial, representing 50% of the target enrolment in this Stratum. TACTT3 is a randomized, placebo-controlled double-blind trial conducted in several European countries to evaluate AM-101 in the treatment of inner ear tinnitus following traumatic cochlear injury or otitis media. Participants in the TACTT3 trial receive three intratympanic injections of AM-101 0.87 mg/mL or placebo over three to five days and are followed for 84 days. Stratum B of the TACTT3 trial is enrolling patients in the post-acute tinnitus stage, whereas Stratum A is recruiting patients with acute tinnitus. While previous clinical trials with AM-101 had focused on acute tinnitus only, data from a Phase 2 trial suggested that AM-101 might be effective also beyond the three month acute stage. Stratum B is seeking to explore if and to what extent AM-101 could be effective in the treatment of post-acute tinnitus. A planned interim analysis for futility will be performed once the enrolled 150 Stratum B participants will have completed their second follow-up visit on Day 35.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use